# Inotropes {#sec-inotropes}

Inotropes are drugs that ↑ force and velocity of myocardial contraction, causing a primary ↑ SV and a secondary ↑ in CO and BP. Inotropes are divided based on their effect on SVR into:

* Standard inotropes\
Catecholamines (or derived), which act to ↑ cAMP.
* Inodilators\
Phosphodiesterase inhibitors. 

:::column-margin
Although we like to conceptually separate inotropes from @sec-vasopressors, there is substantial overlap in action between drugs in either class and the umbrella term *vasoactive* is a better fit.
:::

## Practice

* Goal is restoration of tissue perfusion\
Regular clinical assessment.
* Circulatory failure
* Invasive arterial monitoring

## Contraindications


## Comparison

: Catecholamines

+------------------+----------------------------------------+-----------------------------------+
| Drug             | Adrenaline                             | Dobutamine                        |
+==================+========================================+===================================+
| Overview         | Endogenous catecholamine               | Synthetic catecholamine           |
|                  |                                        |                                   |
|                  | * Mixed non-selective α and β activity | * Predominantly β~1~              |
|                  |                                        | * Nonspecific α effects at ↑ dose |
+------------------+----------------------------------------+-----------------------------------+
| Relative Actions | * ↑ Inotropy                           | * ↑ Inotropy                      |
|                  | * ↑ SVR                                | * ↓ SVR                           |
+------------------+----------------------------------------+-----------------------------------+
| Disadvantages    | * ↑ Myocardial O~2~ consumption        | * ↓ SVR\                          |
|                  | * Type B lactataemia                   | Hypotension.                      |
|                  | * Arrhythmogenic                       | * ↑ Myocardial O~2~ consumption   |
|                  |                                        | * Arrhythmogenic                  |
+------------------+----------------------------------------+-----------------------------------+


: Inodilators

+---------------+----------------------------------+---------------------------+
| Drug          | Milrinone                        | Levosimendan              |
+===============+==================================+===========================+
| Overview      |                                  |                           |
|               |                                  |                           |
|               |                                  |                           |
|               |                                  |                           |
+---------------+----------------------------------+---------------------------+
| Advantages    | * ↑ Inotropy                     | * ↑ Inotropy              |
|               | * ↓ SVR                          | * ↓ SVR                   |
|               |                                  | * Long duration of action |
+---------------+----------------------------------+---------------------------+
| Disadvantages | * ↑ Arrhythmia                   | * ↓ SVR                   |
|               | * ↓ SVR                          | * Expensive               |
|               | * Requires loading               |                           |
|               | * Longer t~1/2~ ↓ titrateability |                           |
|               | * Renally cleared                |                           |
+---------------+----------------------------------+---------------------------+


## Key Studies

**Cardiogenic Shock**:

{{< include /trials/doremi.qmd >}}


---

## References

1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.
1. Mathew R, Di Santo P, Jung RG, et al. [Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock](https://www.nejm.org/doi/full/10.1056/NEJMoa2026845). New England Journal of Medicine. 2021;385(6):516-525.
